TipRanks
Santen Pharmaceutical Co Ltd (JP:4536)
:4536
Japanese Market
4536
Santen Pharmaceutical Co
RESEARCH TOOLSreports
Want to see JP:4536 full AI Analyst Report?

Santen Pharmaceutical Co (4536) Ratios

1 Followers

Santen Pharmaceutical Co Ratios

JP:4536's free cash flow for Q2 2026 was ¥0.55. For the 2026 fiscal year, JP:4536's free cash flow was decreased by ¥ and operating cash flow was ¥0.15. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 26Mar 25Mar 24
Liquidity Ratios
Current Ratio
 ― 2.58 2.60 2.54 2.38
Quick Ratio
 ― 1.99 1.87 2.08 1.94
Cash Ratio
 ― 1.07 0.92 1.02 0.65
Solvency Ratio
 ― 0.44 0.44 0.34 0.02
Operating Cash Flow Ratio
 ― 0.70 0.50 0.78 0.42
Short-Term Operating Cash Flow Coverage
 ― 0.00 142.16 26.44 12.16
Net Current Asset Value
¥ ―¥ 100.20B¥ 101.74B¥ 105.81B¥ 85.44B
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.08 0.08 0.08 0.09
Debt-to-Equity Ratio
 ― 0.12 0.12 0.11 0.12
Debt-to-Capital Ratio
 ― 0.11 0.10 0.10 0.11
Long-Term Debt-to-Capital Ratio
 ― 0.08 0.08 0.08 0.09
Financial Leverage Ratio
 ― 1.43 1.42 1.42 1.43
Debt Service Coverage Ratio
 ― 50.68 25.18 9.85 1.12
Interest Coverage Ratio
 ― 51.92 22.68 19.48 21.36
Debt to Market Cap
 ― 0.05 0.05 0.06 0.07
Interest Debt Per Share
 ― 100.51 112.16 103.09 97.33
Net Debt to EBITDA
 ― -0.89 -0.68 -1.05 -1.52
Profitability Margins
Gross Profit Margin
―54.40%55.20%59.18%59.52%
EBIT Margin
―16.19%16.95%12.68%-1.06%
EBITDA Margin
―22.17%23.25%18.70%5.12%
Operating Profit Margin
―18.74%15.50%17.19%11.47%
Pretax Profit Margin
―15.83%16.27%9.89%-2.08%
Net Profit Margin
―12.09%12.81%8.82%-5.36%
Continuous Operations Profit Margin
―11.95%12.88%8.84%-5.37%
Net Income Per EBT
―76.36%78.77%89.18%257.77%
EBT Per EBIT
―84.44%104.93%57.56%-18.11%
Return on Assets (ROA)
―8.86%8.83%6.11%-3.55%
Return on Equity (ROE)
―12.67%12.58%8.70%-5.08%
Return on Capital Employed (ROCE)
―17.44%13.49%15.14%9.65%
Return on Invested Capital (ROIC)
―13.05%10.57%13.42%9.56%
Return on Tangible Assets
―10.86%10.64%7.57%-4.60%
Earnings Yield
―7.33%6.39%5.11%-3.41%
Efficiency Ratios
Receivables Turnover
 ― 4.16 4.06 3.34 2.60
Payables Turnover
 ― 3.51 3.70 5.13 4.47
Inventory Turnover
 ― 2.65 2.02 2.85 2.87
Fixed Asset Turnover
 ― 4.11 3.73 4.22 4.22
Asset Turnover
 ― 0.73 0.69 0.69 0.66
Working Capital Turnover Ratio
 ― 2.14 2.10 2.26 2.17
Cash Conversion Cycle
 ― 121.32 171.57 166.13 185.65
Days of Sales Outstanding
 ― 87.70 89.90 109.44 140.18
Days of Inventory Outstanding
 ― 137.65 180.42 127.88 127.17
Days of Payables Outstanding
 ― 104.03 98.76 71.20 81.70
Operating Cycle
 ― 225.35 270.33 237.32 267.35
Cash Flow Ratios
Operating Cash Flow Per Share
 ― 174.78 132.77 198.01 95.88
Free Cash Flow Per Share
 ― 155.67 111.88 168.88 32.42
CapEx Per Share
 ― 19.11 20.89 29.13 63.47
Free Cash Flow to Operating Cash Flow
 ― 0.89 0.84 0.85 0.34
Dividend Paid and CapEx Coverage Ratio
 ― 3.25 2.23 3.22 1.00
Capital Expenditure Coverage Ratio
 ― 9.15 6.36 6.80 1.51
Operating Cash Flow Coverage Ratio
 ― 1.79 1.25 2.07 1.03
Operating Cash Flow to Sales Ratio
 ― 0.20 0.15 0.24 0.13
Free Cash Flow Yield
―10.98%6.27%11.89%2.87%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― 13.64 15.66 19.55 -29.29
Price-to-Sales (P/S) Ratio
 ― 1.65 2.01 1.73 1.57
Price-to-Book (P/B) Ratio
 ― 1.73 1.97 1.70 1.49
Price-to-Free Cash Flow (P/FCF) Ratio
 ― 9.11 15.96 8.41 34.86
Price-to-Operating Cash Flow Ratio
 ― 8.11 13.45 7.17 11.79
Price-to-Earnings Growth (PEG) Ratio
 ― 0.32 1.62 -0.07 0.19
Price-to-Fair Value
 ― 1.73 1.97 1.70 1.49
Enterprise Value Multiple
 ― 6.54 7.95 8.18 29.10
Enterprise Value
 ― 435.28B 538.85B 461.56B 416.09B
EV to EBITDA
 ― 6.54 7.95 8.18 29.10
EV to Sales
 ― 1.45 1.85 1.53 1.49
EV to Free Cash Flow
 ― 8.02 14.70 7.45 33.13
EV to Operating Cash Flow
 ― 7.14 12.39 6.35 11.20
Tangible Book Value Per Share
 ― 601.58 684.81 603.86 508.46
Shareholders’ Equity Per Share
 ― 821.11 906.49 834.19 758.81
Tax and Other Ratios
Effective Tax Rate
 ― 0.24 0.21 0.11 -1.58
Revenue Per Share
 ― 860.58 890.12 823.04 720.24
Net Income Per Share
 ― 104.00 114.06 72.62 -38.58
Tax Burden
 ― 0.76 0.79 0.89 2.58
Interest Burden
 ― 0.98 0.96 0.78 1.97
Research & Development to Revenue
 ― 0.08 0.09 0.08 0.10
SG&A to Revenue
 ― 0.28 0.31 0.30 0.34
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 1.68 1.16 2.73 -2.48
Currency in JPY